Introduction {#sec0001}
============

Diarrhea and changes in taste are among the most prevalent gastrointestinal (GI) symptoms of COVID-19 disease and can occur in nearly 50% of patients[@bib0001] ^,^ [@bib0002]. Clinical and virological aspects of enteric COVID-19 disease have been reviewed, with authors suggesting the need for study of possible fecal-oral transmission[@bib0001] ^,^ [@bib0003]. Such studies are justified by observed GI symptoms and detection of positive stool samples. In children, initial GI symptoms may be mild and transient[@bib0004], but a case has been reported of positive fecal tests occurring in the absence of positive nasopharyngeal tests or respiratory symptoms[@bib0005]. The purposes of this brief report are to emphasize the importance of testing stool samples under certain conditions and to suggest a novel route of direct enterocyte infection by COVID-19 in cases of developmental or acquired hypochlorhydria.

Hypochlorhydria and Oral Infection {#sec0002}
==================================

Many defenses exist in the upper parts of the GI system to protect against infection by ingested pathogens. The low pH (1.5-3.0) of gastric acid is a particularly important one. In cases of hypochlorhydria (low stomach acid), the gastric environmental pH is raised to pH 3-5. For this reason, hypochlorhydria is associated with an increased risk for enteric infection[@bib0006] ^,^ [@bib0007]. A large proportion of the human population suffers from hypochlorhydria. For example, gastric acid secretion is often depressed in the elderly[@bib0006], a high-risk population for contracting COVID-19 disease. Acquired *H. pylori* infection and the use of proton pump inhibitors (PPI) are also associated with low stomach acid[@bib0007], as is stress[@bib0008].

COVID-19 virus may not survive normal gastric acid pH levels of 1.5-3, but there is evidence that it can survive a pH level of 3 or above[@bib0009]. If COVID-19 virus can resist the pH levels of 3-5 typical of hypochlorhydria, it would have a route from mouth to intestine, where the virus could directly infect ACE2-bearing enterocytes there[@bib0001].

Although there is observational evidence that long-term or high-level use of PPI is associated with an increased risk of testing positive for COVID-19[@bib0010], certain histamine-2 receptor antagonists (H2RA) and a PPI have been observed to improve disease outcome in patients already infected with COVID-19 virus[@bib0011]. This improvement in disease outcome is reportedly due to negative effects of the drugs on viral replication or on viral enzyme activity[@bib0011]. Thus, roles of both PPI and H2RA in COVID-19 disease merit further study.

To date, COVID-19 transmission through ingestion of contaminated food is not considered a concern. However, the route of virus delivery that results in GI symptoms and fecal shedding might still be oral. The fact that changes in taste can be an early symptom of COVID-19 infection[@bib0002] suggests that the virus does enter and infect the mouth. During exercise, occupational exertion, eating, drinking, or vocalizing, the mouth could be the recipient of infected droplets or aerosols. Thus, oral delivery of virus may occur, particularly in those not wearing masks at the time of exposure.

In fecal-oral transmission, the organism initially enters the body through the mouth. For COVID-19, evidence that the gut is infected directly, and not secondarily to respiratory infection, is provided by negative nasopharyngeal tests in the presence of positive fecal samples collected simultaneously[@bib0005]. Escape through the compromised gastric acid defense system of hypochlorhydria could give COVID-19 virus access to intestinal enterocytes. Hypothetically, the initial infection of an individual could occur there.

Significance of COVID-19 Detection in Stool {#sec0003}
===========================================

COVID-19 viral RNA has been detected in stool samples[@bib0001] ^,^ [@bib0003], [@bib0004], [@bib0005], as has intact virus[@bib0012]. Infectivity of a fecal isolate in Vero E cell culture has been described[@bib0013]. Actual transmission of COVID-19 disease to another person through the fecal-oral route has not been reported. SARS-CoV-1, a coronavirus with 80% genomic nucleotide identity to COVID-19 virus[@bib0001], was also detected in patient stool samples[@bib0001] ^,^ [@bib0003] ^,^ [@bib0014]. In the case of SARS-CoV-1, fecal virus was shown to remain viable for 4 days as demonstrated by infection of Vero E cells in culture[@bib0014]. Certainly, being infectious in cell culture is no indication that fecal virus is a contagion threat to people, but it does suggest that all of the viral RNA detected in stool was and is not simply excreted nucleic acid remnants. Definitive proof that fecal COVID-19 RNA represents infective virus must await basic research. A recent review of our current understanding of COVID-19 viral transmission[@bib0015] is recommended to interested readers.

It should be noted that widespread fecal testing of all COVID-19 patients with diarrhea is neither warranted nor prudent. There are many potential causes of diarrhea in hospitalized COVID-19 patients. Among them are the alterations in intestinal microflora associated with antiviral or antibiotic drug treatments, with non-enteric nutrition, or with pre-existing GI illness[@bib0016]. Evidence of direct cytopathic effects on enterocytes should be explored before testing for COVID-19 viral markers[@bib0016]. The indiscriminate use of fecal testing would be a waste of resources needed elsewhere and false positive results could lead to inappropriate conclusions or non-productive recommendations. Potential other causes of diarrhea in patients should be explored before stool testing for COVID-19 viral markers is initiated.

Conclusions {#sec0004}
===========

The significance of COVID-19 viral RNA detected in stool samples remains to be determined, but the observation raises the question of fecal-oral transmission. If such transmission occurs, a negative test result for virus of respiratory origin might not mean that recovering patients are no longer contagious. Patients with no evidence of respiratory shedding could still be contagious by fecal shedding and oral transmission. If individuals with hypochlorhydria are susceptible to infection by oral exposure, the prevalence of low stomach acid in the population could lead to further transmission. Fecal-oral transmission would be in addition to the airborne transmission already identified. Thus, hypochlorhydria may lead to less efficient, but equally dangerous, transmission of COVID-19 disease.
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